Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Brevinin-2GHk from Sylvirana guentheri and the Design of Truncated Analogs Exhibiting the Enhancement of Antimicrobial Activity.

Chen G, Miao Y, Ma C, Zhou M, Shi Z, Chen X, Burrows JF, Xi X, Chen T, Wang L.

Antibiotics (Basel). 2020 Feb 14;9(2). pii: E85. doi: 10.3390/antibiotics9020085.

2.

Design of N-Terminal Derivatives from a Novel Dermaseptin Exhibiting Broad-Spectrum Antimicrobial Activity against Isolates from Cystic Fibrosis Patients.

Ying Y, Wang H, Xi X, Ma C, Liu Y, Zhou M, Du Q, Burrows JF, Wei M, Chen T, Wang L.

Biomolecules. 2019 Oct 24;9(11). pii: E646. doi: 10.3390/biom9110646.

3.

A Novel Dermaseptin Isolated from the Skin Secretion of Phyllomedusa tarsius and Its Cationicity-Enhanced Analogue Exhibiting Effective Antimicrobial and Anti-Proliferative Activities.

Li M, Xi X, Ma C, Chen X, Zhou M, Burrows JF, Chen T, Wang L.

Biomolecules. 2019 Oct 18;9(10). pii: E628. doi: 10.3390/biom9100628.

4.

Discovery and Rational Design of a Novel Bowman-Birk Related Protease Inhibitor.

Miao Y, Chen G, Xi X, Ma C, Wang L, Burrows JF, Duan J, Zhou M, Chen T.

Biomolecules. 2019 Jul 14;9(7). pii: E280. doi: 10.3390/biom9070280.

5.

Structure-activity relationship of an antimicrobial peptide, Phylloseptin-PHa: balance of hydrophobicity and charge determines the selectivity of bioactivities.

Liu Y, Du Q, Ma C, Xi X, Wang L, Zhou M, Burrows JF, Chen T, Wang H.

Drug Des Devel Ther. 2019 Jan 23;13:447-458. doi: 10.2147/DDDT.S191072. eCollection 2019.

6.

USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells.

McCann AP, Smyth P, Cogo F, McDaid WJ, Jiang L, Lin J, Evergren E, Burden RE, Van Schaeybroeck S, Scott CJ, Burrows JF.

Cell Commun Signal. 2018 Nov 8;16(1):77. doi: 10.1186/s12964-018-0291-5.

7.

A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells.

Chen X, Zhang L, Ma C, Zhang Y, Xi X, Wang L, Zhou M, Burrows JF, Chen T.

Biosci Rep. 2018 Nov 9;38(6). pii: BSR20180710. doi: 10.1042/BSR20180710. Print 2018 Dec 21.

8.

Biological Activities of Cationicity-Enhanced and Hydrophobicity-Optimized Analogues of an Antimicrobial Peptide, Dermaseptin-PS3, from the Skin Secretion of Phyllomedusa sauvagii.

Tan Y, Chen X, Ma C, Xi X, Wang L, Zhou M, Burrows JF, Kwok HF, Chen T.

Toxins (Basel). 2018 Aug 7;10(8). pii: E320. doi: 10.3390/toxins10080320.

9.

Identification of novel Amurin-2 variants from the skin secretion of Rana amurensis, and the design of cationicity-enhanced analogues.

Zhang L, Chen X, Zhang Y, Ma C, Xi X, Wang L, Zhou M, Burrows JF, Chen T.

Biochem Biophys Res Commun. 2018 Mar 18;497(4):943-949. doi: 10.1016/j.bbrc.2018.01.124. Epub 2018 Jan 31.

PMID:
29366784
10.

Identification and target-modifications of temporin-PE: A novel antimicrobial peptide in the defensive skin secretions of the edible frog, Pelophylax kl. esculentus.

Sang M, Wu Q, Xi X, Ma C, Wang L, Zhou M, Burrows JF, Chen T.

Biochem Biophys Res Commun. 2018 Jan 22;495(4):2539-2546. doi: 10.1016/j.bbrc.2017.11.173. Epub 2017 Nov 28.

PMID:
29191658
11.

Evaluation of patient satisfaction in pediatric dermatology.

Ahmed S, Miller J, Burrows JF, Bertha BK, Rosen P.

Pediatr Dermatol. 2017 Nov;34(6):668-672. doi: 10.1111/pde.13294.

PMID:
29144047
12.

Predictors of Patient Satisfaction in Pediatric Oncology.

Davis J, Burrows JF, Ben Khallouq B, Rosen P.

J Pediatr Oncol Nurs. 2017 Nov/Dec;34(6):435-438. doi: 10.1177/1043454217717239. Epub 2017 Jul 1.

PMID:
28670954
13.

Key drivers of patient experience in ambulatory paediatric cardiology.

Allam SD, Mehta M, Ben Khallouq B, Burrows JF, Rosen P.

Cardiol Young. 2017 Oct;27(8):1585-1590. doi: 10.1017/S1047951117000841. Epub 2017 May 18.

PMID:
28516822
14.

Deubiquitylating enzymes in receptor endocytosis and trafficking.

McCann AP, Scott CJ, Van Schaeybroeck S, Burrows JF.

Biochem J. 2016 Dec 15;473(24):4507-4525. Review.

PMID:
27941029
15.

Unlocking the Doors to Patient Satisfaction in Pediatric Orthopaedics.

Peng FB, Burrows JF, Shirley ED, Rosen P.

J Pediatr Orthop. 2018 Sep;38(8):398-402. doi: 10.1097/BPO.0000000000000837.

PMID:
27442213
16.

Factors Influencing Patient Experience in Pediatric Neurology.

Singh SC, Sheth RD, Burrows JF, Rosen P.

Pediatr Neurol. 2016 Jul;60:37-41. doi: 10.1016/j.pediatrneurol.2016.04.002. Epub 2016 Apr 12.

PMID:
27238409
17.

Extracellular cathepsin S and intracellular caspase 1 activation are surrogate biomarkers of particulate-induced lysosomal disruption in macrophages.

Hughes CS, Colhoun LM, Bains BK, Kilgour JD, Burden RE, Burrows JF, Lavelle EC, Gilmore BF, Scott CJ.

Part Fibre Toxicol. 2016 Apr 23;13:19. doi: 10.1186/s12989-016-0129-5.

18.

Physician Engagement in the Transformation of the Pediatric Patient Experience.

Rosen P, Burrows JF, Greenspan JS.

J Pediatr. 2016 Feb;169:4-5. doi: 10.1016/j.jpeds.2015.11.023. No abstract available.

PMID:
26810098
19.

Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation.

Spence S, Greene MK, Fay F, Hams E, Saunders SP, Hamid U, Fitzgerald M, Beck J, Bains BK, Smyth P, Themistou E, Small DM, Schmid D, O'Kane CM, Fitzgerald DC, Abdelghany SM, Johnston JA, Fallon PG, Burrows JF, McAuley DF, Kissenpfennig A, Scott CJ.

Sci Transl Med. 2015 Sep 2;7(303):303ra140. doi: 10.1126/scitranslmed.aab3459.

PMID:
26333936
20.

USP17 is required for clathrin mediated endocytosis of epidermal growth factor receptor.

Jaworski J, de la Vega M, Fletcher SJ, McFarlane C, Greene MK, Smyth AW, Van Schaeybroeck S, Johnston JA, Scott CJ, Rappoport JZ, Burrows JF.

Oncotarget. 2014 Aug 30;5(16):6964-75.

21.

A novel RCE1 isoform is required for H-Ras plasma membrane localization and is regulated by USP17.

Jaworski J, Govender U, McFarlane C, de la Vega M, Greene MK, Rawlings ND, Johnston JA, Scott CJ, Burrows JF.

Biochem J. 2014 Jan 15;457(2):289-300. doi: 10.1042/BJ20131213.

PMID:
24134311
22.

A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity.

Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hülsmeyer M, Trentmann S, Jensen K, Hohlbaum AM, Audoly L.

Mol Cancer Ther. 2013 Nov;12(11):2459-71. doi: 10.1158/1535-7163.MCT-13-0318. Epub 2013 Sep 3.

23.

Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularization.

Small DM, Burden RE, Jaworski J, Hegarty SM, Spence S, Burrows JF, McFarlane C, Kissenpfennig A, McCarthy HO, Johnston JA, Walker B, Scott CJ.

Int J Cancer. 2013 Nov;133(9):2102-12. doi: 10.1002/ijc.28238. Epub 2013 May 29.

24.

Enhanced antitumor activity of the photosensitizer meso-Tetra(N-methyl-4-pyridyl) porphine tetra tosylate through encapsulation in antibody-targeted chitosan/alginate nanoparticles.

Abdelghany SM, Schmid D, Deacon J, Jaworski J, Fay F, McLaughlin KM, Gormley JA, Burrows JF, Longley DB, Donnelly RF, Scott CJ.

Biomacromolecules. 2013 Feb 11;14(2):302-10. doi: 10.1021/bm301858a. Epub 2013 Jan 31.

25.

Regulation of cellular responses by deubiquitinating enzymes: an update.

Burrows JF, Johnston JA.

Front Biosci (Landmark Ed). 2012 Jan 1;17:1184-200. Review.

PMID:
22201797
26.

Ubiquitination: Added complexity in Ras and Rho family GTPase function.

de la Vega M, Burrows JF, Johnston JA.

Small GTPases. 2011 Jul;2(4):192-201. Epub 2011 Jul 1.

27.

The deubiquitinating enzyme USP17 is essential for GTPase subcellular localization and cell motility.

de la Vega M, Kelvin AA, Dunican DJ, McFarlane C, Burrows JF, Jaworski J, Stevenson NJ, Dib K, Rappoport JZ, Scott CJ, Long A, Johnston JA.

Nat Commun. 2011 Mar 29;2:259. doi: 10.1038/ncomms1243.

28.
29.

The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression.

McFarlane C, Kelvin AA, de la Vega M, Govender U, Scott CJ, Burrows JF, Johnston JA.

Cancer Res. 2010 Apr 15;70(8):3329-39. doi: 10.1158/0008-5472.CAN-09-4152. Epub 2010 Apr 13.

30.

The deubiquitinating enzyme USP17 blocks N-Ras membrane trafficking and activation but leaves K-Ras unaffected.

de la Vega M, Burrows JF, McFarlane C, Govender U, Scott CJ, Johnston JA.

J Biol Chem. 2010 Apr 16;285(16):12028-36. doi: 10.1074/jbc.M109.081448. Epub 2010 Feb 10.

31.

Siglec-E is up-regulated and phosphorylated following lipopolysaccharide stimulation in order to limit TLR-driven cytokine production.

Boyd CR, Orr SJ, Spence S, Burrows JF, Elliott J, Carroll HP, Brennan K, Ní Gabhann J, Coulter WA, Jones C, Crocker PR, Johnston JA, Jefferies CA.

J Immunol. 2009 Dec 15;183(12):7703-9. doi: 10.4049/jimmunol.0902780. Erratum in: J Immunol. 2010 Feb 1;184(3):1655. Jones, Claire [added]; Crocker, Paul R [added].

32.

USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity.

Burrows JF, Kelvin AA, McFarlane C, Burden RE, McGrattan MJ, De la Vega M, Govender U, Quinn DJ, Dib K, Gadina M, Scott CJ, Johnston JA.

J Biol Chem. 2009 Apr 3;284(14):9587-95. doi: 10.1074/jbc.M807216200. Epub 2009 Feb 2.

33.

Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase.

Elliott J, Lynch OT, Suessmuth Y, Qian P, Boyd CR, Burrows JF, Buick R, Stevenson NJ, Touzelet O, Gadina M, Power UF, Johnston JA.

J Virol. 2007 Apr;81(7):3428-36. Epub 2007 Jan 24.

34.

SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses.

Orr SJ, Morgan NM, Buick RJ, Boyd CR, Elliott J, Burrows JF, Jefferies CA, Crocker PR, Johnston JA.

J Biol Chem. 2007 Feb 9;282(6):3418-22. Epub 2006 Nov 30.

35.

De-ubiquitinating enzymes: intracellular signalling and disease.

Johnston JA, Burrows JF.

Biochem Soc Trans. 2006 Nov;34(Pt 5):764-9.

PMID:
17052193
36.

CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover.

Orr SJ, Morgan NM, Elliott J, Burrows JF, Scott CJ, McVicar DW, Johnston JA.

Blood. 2007 Feb 1;109(3):1061-8. Epub 2006 Sep 28.

PMID:
17008544
37.

The DUB/USP17 deubiquitinating enzymes, a multigene family within a tandemly repeated sequence.

Burrows JF, McGrattan MJ, Johnston JA.

Genomics. 2005 Apr;85(4):524-9.

PMID:
15780755
38.

DUB-3, a cytokine-inducible deubiquitinating enzyme that blocks proliferation.

Burrows JF, McGrattan MJ, Rascle A, Humbert M, Baek KH, Johnston JA.

J Biol Chem. 2004 Apr 2;279(14):13993-4000. Epub 2003 Dec 29.

39.

Altered expression of the septin gene, SEPT9, in ovarian neoplasia.

Burrows JF, Chanduloy S, McIlhatton MA, Nagar H, Yeates K, Donaghy P, Price J, Godwin AK, Johnston PG, Russell SE.

J Pathol. 2003 Dec;201(4):581-8.

PMID:
14648661
40.

Genomic organization, complex splicing pattern and expression of a human septin gene on chromosome 17q25.3.

McIlhatton MA, Burrows JF, Donaghy PG, Chanduloy S, Johnston PG, Russell SE.

Oncogene. 2001 Sep 13;20(41):5930-9.

41.

Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors.

Russell SE, McIlhatton MA, Burrows JF, Donaghy PG, Chanduloy S, Petty EM, Kalikin LM, Church SW, McIlroy S, Harkin DP, Keilty GW, Cranston AN, Weissenbach J, Hickey I, Johnston PG.

Cancer Res. 2000 Sep 1;60(17):4729-34.

Supplemental Content

Loading ...
Support Center